376 related articles for article (PubMed ID: 28276705)
1. Exploring the epigenetic drug discovery landscape.
Prachayasittikul V; Prathipati P; Pratiwi R; Phanus-Umporn C; Malik AA; Schaduangrat N; Seenprachawong K; Wongchitrat P; Supokawej A; Prachayasittikul V; Wikberg JE; Nantasenamat C
Expert Opin Drug Discov; 2017 Apr; 12(4):345-362. PubMed ID: 28276705
[TBL] [Abstract][Full Text] [Related]
2. Current trends in epigenetic drug discovery.
Stolfa DA; Einsle O; Sippl W; Jung M
Future Med Chem; 2012 Oct; 4(16):2029-37. PubMed ID: 23157236
[TBL] [Abstract][Full Text] [Related]
3. Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back.
Bosia M; Pigoni A; Cavallaro R
Expert Opin Drug Discov; 2015 Feb; 10(2):125-39. PubMed ID: 25345474
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome.
Chatterjee P; Roy D; Rathi N
J Alzheimers Dis; 2018; 61(1):53-65. PubMed ID: 29199645
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic prospects for epigenetic modulation.
Heightman TD
Expert Opin Ther Targets; 2011 Jun; 15(6):729-40. PubMed ID: 21366500
[TBL] [Abstract][Full Text] [Related]
6. Prospects for the development of epigenetic drugs for CNS conditions.
Szyf M
Nat Rev Drug Discov; 2015 Jul; 14(7):461-74. PubMed ID: 26000723
[TBL] [Abstract][Full Text] [Related]
7. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
Vogelmann A; Robaa D; Sippl W; Jung M
Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on the discovery of small-molecule modulators for epigenetic processes.
Lu Q; Quinn AM; Patel MP; Semus SF; Graves AP; Bandyopadhyay D; Pope AJ; Thrall SH
J Biomol Screen; 2012 Jun; 17(5):555-71. PubMed ID: 22392809
[TBL] [Abstract][Full Text] [Related]
9. Improving attrition rates in Ebola virus drug discovery.
Glisic S; Paessler S; Veljkovic N; Perovic VR; Prljic J; Veljkovic V
Expert Opin Drug Discov; 2015; 10(9):1025-32. PubMed ID: 26125997
[TBL] [Abstract][Full Text] [Related]
10. Two-hit wonders: The expanding universe of multitargeting epigenetic agents.
de Lera AR; Ganesan A
Curr Opin Chem Biol; 2020 Aug; 57():135-154. PubMed ID: 32784072
[TBL] [Abstract][Full Text] [Related]
11. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic drug discovery: a success story for cofactor interference.
Ganesan A
Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685973
[TBL] [Abstract][Full Text] [Related]
13. Recent progress on cheminformatics approaches to epigenetic drug discovery.
Sessions Z; Sánchez-Cruz N; Prieto-Martínez FD; Alves VM; Santos HP; Muratov E; Tropsha A; Medina-Franco JL
Drug Discov Today; 2020 Dec; 25(12):2268-2276. PubMed ID: 33010481
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.
Amodio N; D'Aquila P; Passarino G; Tassone P; Bellizzi D
Expert Opin Ther Targets; 2017 Jan; 21(1):91-101. PubMed ID: 27892767
[TBL] [Abstract][Full Text] [Related]
15. Computational approaches for innovative antiepileptic drug discovery.
Talevi A
Expert Opin Drug Discov; 2016 Oct; 11(10):1001-16. PubMed ID: 27454246
[TBL] [Abstract][Full Text] [Related]
16. Identification of drug candidates and repurposing opportunities through compound-target interaction networks.
Cichonska A; Rousu J; Aittokallio T
Expert Opin Drug Discov; 2015 Dec; 10(12):1333-45. PubMed ID: 26429153
[TBL] [Abstract][Full Text] [Related]
17. The timeline of epigenetic drug discovery: from reality to dreams.
Ganesan A; Arimondo PB; Rots MG; Jeronimo C; Berdasco M
Clin Epigenetics; 2019 Dec; 11(1):174. PubMed ID: 31791394
[TBL] [Abstract][Full Text] [Related]
18. Using reverse docking for target identification and its applications for drug discovery.
Lee A; Lee K; Kim D
Expert Opin Drug Discov; 2016 Jul; 11(7):707-15. PubMed ID: 27186904
[TBL] [Abstract][Full Text] [Related]
19. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Cacabelos R
Drug Dev Res; 2014 Sep; 75(6):348-65. PubMed ID: 25195579
[TBL] [Abstract][Full Text] [Related]
20. Drug discovery for epigenetics targets.
Holdgate GA; Bardelle C; Lanne A; Read J; O'Donovan DH; Smith JM; Selmi N; Sheppard R
Drug Discov Today; 2022 Apr; 27(4):1088-1098. PubMed ID: 34728375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
